About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

Group 1 - Amgen Inc. is recognized as one of the 11 cheap quarterly dividend stocks to buy currently [1] - The company has a strong and diverse portfolio with over two dozen brands, including several blockbuster drugs generating over $1 billion in annual sales [2] - Amgen's medicines cover multiple therapeutic areas, including heart health, bone health, and psoriasis treatment [3] Group 2 - In the second quarter, Amgen reported revenue of $9.2 billion, reflecting a 9% increase from the previous year, while adjusted earnings per share rose 21% to $6.02 [4] - The company has demonstrated consistent dividend growth for 14 consecutive years, currently offering a quarterly dividend of $2.38 per share and a dividend yield of 3.32% as of September 23 [4]

Core Insights - Davis Commodities Limited is evaluating the expansion of its Real Yield Token (RYT) infrastructure into a multi-billion-dollar framework that connects sustainable agriculture with health innovation [1][2] - The company is exploring how RYT infrastructure could facilitate programmable, yield-backed financing for longevity and biotech sectors, leveraging over USD 12.5 billion committed by private capital [2][3] - The initiative is in an exploratory phase, with no commitment to token issuance or commercialization at this stage [3] Company Overview - Davis Commodities Limited is based in Singapore and specializes in trading agricultural commodities such as sugar, rice, and oil and fat products across various markets including Asia, Africa, and the Middle East [4] - The company operates under two main brands, Maxwill and Taffy, and provides complementary services like warehouse handling, storage, and logistics [4] - As of the fiscal year ended December 31, 2024, the company distributes its products to customers in over 20 countries [4] Financial and Operational Insights - The company has identified over USD 1 billion in tokenized issuance capacity for emerging-market agriculture and health-tech initiatives [8] - RYT-based liquidity pools are projected to achieve a settlement velocity that is over 20% faster than traditional trade finance mechanisms [8] - The company is focusing on ESG-oriented reserve structures that link food-chain asset performance with biotech innovation capital pools [8]

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Market Overview - U.S. stocks traded lower, with the Nasdaq Composite falling more than 1% on Thursday, while the Dow decreased by 0.50% to 45,889.75 and the S&P 500 dropped 0.94% to 6,575.35 [1] - Consumer staples shares increased by 0.5% on Thursday, contrasting with a 1.5% decline in communication services stocks [1][2] Economic Indicators - Initial jobless claims decreased by 14,000 to 218,000 in the third week of September, better than market estimates of 235,000 [3][12] - U.S. wholesale inventories fell by 0.2% month-over-month to $898.8 billion in August, against expectations of a 0.1% increase [12] - Durable goods orders rose by 2.9% month-over-month to $312.1 billion in August, surpassing market estimates of a 0.5% decline [12] - The U.S. trade deficit in goods narrowed by $17.3 billion to $85.5 billion in August, compared to market estimates of $95.65 billion [12] - The U.S. economy grew at an annualized rate of 3.8% in the second quarter, an increase from the previous estimate of 3.3% [12] Commodity Market - Oil prices decreased by 0.5% to $64.66, while gold fell by 0.1% to $3,766.60 [6] - Silver prices increased by 1.4% to $44.805, whereas copper declined by 0.6% to $4.7865 [6] Company Performance - PepGen Inc. shares surged 107% to $5.51 following the announcement of a $100 million public offering priced at $3.20 per share [10] - SciSparc Ltd. shares rose 79% to $6.86 after announcing a quantum computing-enabled 3D protein modeling initiative [10] - Plus Therapeutics, Inc. shares increased by 40% to $0.5640 due to a national coverage agreement with UnitedHealthcare [10] - SeaStar Medical Holding Corporation shares plummeted 50% to $0.6226 after a recommendation to continue a pivotal trial [10] - Erayak Power Solution Group Inc. shares fell 31% to $0.0493 after a previous jump [10] - Cemtrex, Inc. shares dropped 29% to $0.4470 following the approval of a reverse stock split [10]

Core Points - PCI Biotech has announced an update regarding the evaluation of its future operations following the discontinuation of the PCL technology development due to insufficient progress and increased project risks [2][3] - The company's immediate priority is to preserve value while exploring strategic alternatives, including reverse mergers or a structured wind-down of operations [3][4] - Current operations are now focused on evaluating a new bioprocessing technology from an undisclosed party, leading to a decision to downsize personnel and extend the wind-down of operations [4][5] Company Overview - PCI Biotech is a biopharmaceutical company that develops and commercializes new technologies and therapies through its photochemical technology platform, which originated from research at the Oslo University Hospital [5]

Core Insights - Capricor Therapeutics announced a regulatory update regarding its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), following a Type A meeting with the FDA after receiving a Complete Response Letter (CRL) in July 2025 [1][2][3] Regulatory Update - The Type A meeting aimed to establish a path toward potential approval of Deramiocel, with key outcomes providing clarity on the regulatory strategy and the opportunity to use HOPE-3 data for approval if it meets regulatory requirements [2][3] - The FDA has aligned with Capricor on endpoints for the HOPE-3 pivotal trial, which is expected to support the BLA resubmission [7][8] Clinical Trials - The HOPE-3 trial is designed to validate findings from previous studies (HOPE-2 and HOPE-2-OLE) that demonstrated significant benefits in cardiac and skeletal muscle function [3][8] - The trial consists of two cohorts evaluating the safety and efficacy of Deramiocel in DMD participants, with 105 subjects enrolled [11] Financial Position - Capricor maintains a strong financial position to support the advancement of Deramiocel through regulatory review and potential launch [4] Product Information - Deramiocel (CAP-1002) is composed of allogeneic cardiosphere-derived cells (CDCs) that have shown immunomodulatory and anti-fibrotic actions in preserving muscle function in muscular dystrophies [9][12] - The product has received multiple designations, including Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which may qualify Capricor for a Priority Review Voucher upon approval [10]

Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under management to more than $1.4bn. The move aims to bolster investments in biotech and digital health innovations, aligning with Sanofi's strategic focus on immunology, neurology, vaccines and rare diseases. Established in 2012, Sanofi Ventures has invested $800m in more than 70 companies, targeting early-stage and emerging opportunities in healthcare. The fund participates in various stage ...

Group 1 - PepGen Inc. is a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases [1] - The company announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a public price of $3.20 per share [1] - The aggregate gross proceeds from this offering are expected to be $100 million before deducting any expenses [1]

Core Insights - Cidara Therapeutics is focused on developing innovative anti-infective therapies, particularly through its Cloudbreak® platform for drug-Fc conjugates aimed at serious infections [1] - The company has received an optimistic price target of $153 from JMP Securities, indicating a potential increase of 73.23% from its current trading price [2][6] - Cidara's Phase 3 trial for CD388, a non-vaccine treatment for seasonal influenza, has been accelerated to start in fall 2025 following a positive meeting with the FDA [3][6] Company Developments - The Phase 3 trial for CD388 will now include a broader population, targeting adults over 65, individuals with high-risk co-morbidities, and those with compromised immune systems, which may enhance the drug's market appeal [4][6] - As of the latest update, Cidara's stock is priced at $88.58, reflecting a 20.53% increase, with a market capitalization of $2.25 billion [5]